Alvotech's stock plummeted 5.11% during Tuesday's intraday trading session, reflecting significant selling pressure on the biopharmaceutical company.

The sharp decline appears to be driven by negative analyst actions, with both Deutsche Bank and Barclays significantly reducing their price targets for Alvotech. Deutsche Bank lowered its target to $4 from $8 while maintaining a Hold rating, representing a 50% reduction. Similarly, Barclays cut its target to $4 from $5 and maintained an Underweight rating on the shares.

These substantial downward revisions by major financial institutions likely contributed to investor concerns about Alvotech's valuation and future prospects, prompting the sell-off during the trading day.